Updated Figures, page-59

Nice solid uptrend formed here now and supply looks limited after plenty have been soaked.

Plenty of chances we will see news from the quarterly as according to their latest announcements they were close to finalising funding arrangements for the PaaS, expanding into other parts of South America, the new verticals; pathology and cardiology and of course more contracts.

In the quarterly I'm looking for growth in revenues, $1.5m to $2m plus in receipts and confirmation that the FDA approval papers were released well into last quarter. Which would mean as stated a possible approval this quarter.

Worth comparing to VHT and PME again as the margin between them keeps increasing.